Press

Mindbloom Announces Partnership with SHIFT To Offer Affordable At-Home Ketamine Therapy To Its Employees

Apr 26 • 3 min read

-Mindbloom, the world’s largest provider of ketamine therapy, announced today a partnership with SHIFT, a tech-enabled management consulting firm, to provide at-home ketamine therapy as a benefit to its employees. Through this partnership, all SHIFT employees will have access to at-home ketamine therapy through Mindbloom for a fraction of the normal price. “I am incredibly proud…

Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease With a Proprietary formulation Based On 5-MeO-DMT

Apr 26 • 3 min read

Biomind Labs Inc. (NEO: BMND / OTC: BMNDF / FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT“)-based BMND08…

Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds

Apr 26 • 3 min read

Mindset Pharma Inc. (CSE: MSET / FSE: 9DF / OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (“PCT”) for the protection of certain of Mindset’s non-hallucinogenic…

Moon Equity Holdings to Sell BitGift Asset to Silo Wellness in Exchange for a Dividend

Apr 26 • 4 min read

Moon Equity Holdings Corp (OTC: MONI) has signed a binding letter of intent (“LOI”) to divest its BitGift asset to Silo Wellness Inc. ( CSE: SILO / OTCQB: SILFF / FSE: 3K7A), an Oregon-based psychedelics company, for a sum up to CAD$500,000. At closing, MONI plans to allocate the Silo shares as a dividend to…

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

Apr 25 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will host a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference being held on April 25-26 at the Metro Toronto…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441